We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more call options, than puts

Call options by funds: $805K | Put options by funds: $456K

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

4% more funds holding

Funds holding: 113 → 118 (+5)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

1% less capital invested

Capital invested by funds: $216M → $213M (-$2.47M)

Holders
118
Holders Change
+5
Holders Change %
+4.42%
% of All Funds
1.86%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
38
Reduced
25
Closed
17
Calls
$805K
Puts
$456K
Net Calls
+$349K
Net Calls Change
+$956K

Top Buyers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
+$1M
2
Millennium Management
Millennium Management
New York
+$950K
3
Citadel Advisors
Citadel Advisors
Florida
+$883K
4
Renaissance Technologies
Renaissance Technologies
New York
+$768K
5
HS
HighVista Strategies
Massachusetts
+$653K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.3M
2
SCM
Stonepine Capital Management
Oregon
-$1.01M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$663K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$361K
5
NCM
Nantahala Capital Management
Connecticut
-$334K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$32M – – –
TCM
2
TCG Crossover Management
California
$18.4M – – –
CC
3
Commodore Capital
New York
$17.8M +$1M +318,604 +6%
BlackRock
4
BlackRock
New York
$17M +$447K +142,081 +3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$11.9M +$170K +53,919 +1%
Osaic Holdings
6
Osaic Holdings
Arizona
$11M – – –
Millennium Management
7
Millennium Management
New York
$7.38M +$950K +301,913 +15%
BBA
8
Baker Bros. Advisors
New York
$6.75M – – –
NCM
9
Nantahala Capital Management
Connecticut
$5.89M -$334K -106,145 -5%
FCMI
10
Foresite Capital Management IV
California
$5.56M – – –
ACM
11
Altium Capital Management
New York
$5.44M – – –
DCM
12
DAFNA Capital Management
California
$5.26M -$299K -95,000 -5%
FCMI
13
Foresite Capital Management III
California
$5.11M – – –
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
$4.67M +$157K +50,000 +3%
LCM
15
Lynx1 Capital Management
Puerto Rico
$4.32M +$515K +163,537 +13%
State Street
16
State Street
Massachusetts
$4.22M +$76.1K +24,160 +2%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$4.09M +$522K +165,743 +14%
JP Morgan Chase
18
JP Morgan Chase
New York
$4.05M -$248K -78,835 -6%
AAA
19
Affinity Asset Advisors
New York
$3.96M +$472K +150,000 +13%
6CM
20
683 Capital Management
New York
$3.42M – – –
Citadel Advisors
21
Citadel Advisors
Florida
$3.01M +$883K +280,443 +41%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$2.93M +$459K +145,965 +18%
Hudson Bay Capital Management
23
Hudson Bay Capital Management
Connecticut
$2.44M +$425K +135,000 +21%
Northern Trust
24
Northern Trust
Illinois
$2.27M +$396K +125,640 +21%
Goldman Sachs
25
Goldman Sachs
New York
$1.75M +$431K +136,996 +32%
1
2 3 4 5

CBAY Hedge Fund Activity: Q1 2022 in Review

118 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2022, worth a combined $213M — down 1.1% from $216M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CBAY positions and 17 closed out — a net gain of 5 holders — while 38 added to existing stakes and 25 trimmed.

The largest buyer was Commodore Capital, adding an estimated $1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.3M sold.

  • 118 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2022, up from 113 in Q4 2021.
  • Funds reported $213M of Cymabay Therapeutics stock for Q1 2022, down 1.1% quarter-over-quarter.
  • 22 funds opened new Cymabay Therapeutics positions in Q1 2022 and 17 closed out, a net change of +5 holders.
  • The largest Cymabay Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $1M added.
  • The largest Cymabay Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $2.3M sold.

Based on aggregated 13F filings for Q1 2022.